“Bernstein Reduces Lamb Weston Target Amid 2027 Profit Fears”
Bernstein SocGen Group diminishes its price target for Lamb Weston (NYSE: LW) from $65 to $46 amidst profit sustainability concerns. The analysis comes following Lamb Weston's Q2 results, foreseeing a possible dip in second-half sales, despite solid performance in the first half of FY26. Investor apprehension heightens around EBITDA guidance and potential international customer profitability. Read more
Read More
“Bernstein Upgrades Gilead; Contained Medicaid Risk Ensures Outperform”
Gilead Sciences retains its Outperform rating from Bernstein SocGen Group, despite recent Medicaid pricing changes. Thanks to Gilead's limited exposure to these changes, its financial impact is predicted to be minimal, ensuring the company's continuous growth and innovative research in the biopharmaceutical industry. Read more
Read More“Gilead Secures Bernstein’s Outperform, Medicaid Risk Contained”
Bernstein SocGen Group maintains a positive Outperform rating on Gilead Sciences, asserting limited financial risk amid Medicaid pricing changes. Primarily affecting Genvoya and Odefsey drugs, which represent a minority portion of their portfolio, Gilead's revenue stability shows resilience to these adjustments, instilling investor assurance. Read more
Read More